FDA Approves ImmuPharma' Pharmacokinetic Study on Lupuzor Therapy
12 Agosto 2021 - 3:15AM
Noticias Dow Jones
By Jaime Llinares Taboada
ImmuPharma PLC said Thursday that the U.S. Food & Drug
Administration has approved the start of the pharmacokinetic study
on its Lupuzor therapy for the treatment of lupus.
The biopharmaceutical company, which focuses on autoimmune
diseases, metabolic diseases, anti-infectives and cancer, said the
pharmacokinetic study will be used to assess the presence of
Lupuzor in the body after administration of single dose.
The study will be carried out in 24 healthy men, and is expected
to take between eight and 12 weeks to complete. Lupuzor will move
into an optimized international Phase 3 trial following the
successful completion of the pharmacokinetic study.
Pharmacokinetics refers to the study of how the body affects a
drug.
Shares at 0749 GMT were flat at 8.62 pence, reversing gains
earlier in the morning.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
August 12, 2021 04:08 ET (08:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De May 2023 a May 2024
